Vascularization potential of a dermal skin substitute material (Biodegradable Temporizing Matrix) by proangiogenic growth factors and ASC - an in ovo study
Diemer M., Strauß S., Bucan V., Busch MA., Dünker N., Vogt PM.
Prospective Study, published in J Mater Sci Mater Med (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Mater Sci Mater Med (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41389228
- PMCID
- PMC12714854
- DOI
- 10.1007/s10856-025-06982-4
Abstract (original English)
In the treatment of severe burn injuries, autologous skin transplantation is increasingly being supplemented by synthetic dermis substitute materials. Novosorb® Biodegradable Temporizing Matrix (BTM) is a polyurethane foam used in a surgical procedure that currently requires a period of up to 21 days for successful neovascularization and integration, which is associated with a longer inpatient treatment. The objective of this study was to assess the efficacy of the growth factors EPO, FGF, PDGF, VEGF and adipogenic stem cells (ASC) in shortening the time required for BTM grafting and vascularization. BTM containing growth factor and/or ASC was grafted onto to the chorioallantoic membrane (CAM) in different configurations. The average vascular growth of the BTM in 9 different experimental groups was analyzed in comparison to the control group. After 7 days, the experiment was terminated, and the vascularization of the BTM was evaluated by macroscopic image analysis with ImageJ/Fiji, along with histological HE staining and immunohistochemical staining for vascular-specific factors. Successful grafting and vascularization of the BTM in ovo were achieved for the first time. The addition of growth factors and ASC increased the average vascularization of the BTM and the entire CAM. All experimental groups showed promising vascularization patterns, with the BTM + ASC and BTM + PDGF +
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.